Streetbeat News

Partnerships

NRXP

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) will present a keynote address on ketamine's efficacy and risks for treating suicidal depression at the Sachs Neuroscience Innovation Forum. The company plans to file a New Drug Application for ketamine in 2024 in the US and EU. NRx has shown ketamine's superiority to placebo and non-inferiority to electroshock therapy in trials. They are developing a new formulation with Nephron Pharmaceuticals and a REMS program. NRx has created HOPE Therapeutics, Inc. to advance ketamine's development and will award rights to shareholders and new investors. NRx is also developing NRX-101 for suicidal bipolar depression and chronic pain, in partnership with Alvogen Pharmaceuticals.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 1:45 pm

CLSK

LBPH

MARA

RIOT

VYGR

Longboard Pharmaceuticals (LBPH) reported positive topline data from its PACIFIC 1b/2a clinical trial of Bexicaserin, with a 53.3% median seizure reduction compared to 20.8% for the placebo group. Voyager Therapeutics (VYGR) announced a capsid license agreement and strategic collaboration with Novartis for gene therapy advancement. Crypto-related stocks like Marathon Digital Holdings (MARA), Riot Blockchain (RIOT), and CleanSpark (CLSK) saw an uptick as Bitcoin's value surpassed $45,000.

Portfolio Pulse from ryanfaloona@benzinga.com

January 02, 2024 | 1:42 pm

IINN

Inspira Technologies (NASDAQ:IINN) has signed a non-binding Letter of Intent with Northwestern Memorial Hospital for the clinical use of its INSPIRA ART100 device, pending FDA clearance. The collaboration will involve Northwestern purchasing disposables for the device and providing usage data to Inspira Technologies. The agreement is contingent on FDA approval expected in the first half of 2024 and a definitive evaluation agreement.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 1:37 pm

GOOG

GOOGL

Alphabet Inc.'s Google Bard, a ChatGPT rival, is seeking user feedback for its 2024 wishlist. Requests include a standalone app, integration with Google Assistant, reduced censorship, fewer hallucinations, and persistent memory. Google is already working on Assistant integration, announced during the Pixel launch in Oct. 2023. A standalone app could benefit iOS users since Google Assistant isn't pre-installed on iOS devices. Persistent memory would help in tasks like debugging code or writing extended texts. Google Bard aims to compete with ChatGPT by adding consumer-facing features.

Portfolio Pulse from Rounak Jain

January 02, 2024 | 1:27 pm

CC

IFF

TROX

Wall Street's most accurate analysts recommend holding three materials stocks with over 3% dividend yields: The Chemours Company (CC), Tronox Holdings plc (TROX), and International Flavors & Fragrances Inc. (IFF). JP Morgan and Morgan Stanley analysts have adjusted their ratings and price targets for CC, with recent weaker-than-expected quarterly results. TROX was downgraded by JP Morgan and upgraded by Credit Suisse, following a 26% decrease in third-quarter revenue. IFF's partnership with Kemira was expanded, and analysts from Stifel and JP Morgan have updated their price targets.

Portfolio Pulse from Avi Kapoor

January 02, 2024 | 1:09 pm

STRM

Streamline Health Solutions, Inc. (NASDAQ:STRM) has expanded its contract with a current client, a 6 facility health system using Oracle Cerner-EHR, to include RevID's automated charge reconciliation and the eValuator Pro Fee module. The client, which has been using eValuator for pre-bill code auditing for over 3 years, also extended the overall agreement term by an additional 3 years.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 12:33 pm

APCX

AppTech Payments Corp. (NASDAQ:APCX) has announced that Reno International Airport is the first international airport to implement its FinZeo platform for payment processing. The platform will handle all financial transactions within the airport. AppTech expects more airports to adopt FinZeo in the near future.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 12:32 pm

SNGX

Soligenix, Inc. announced the publication of a study demonstrating 100% protection by its bivalent vaccine against Sudan ebolavirus and Marburg virus in nonhuman primate models. The study, a collaboration with the University of Hawaiʻi at Mānoa, was published in the journal Vaccine and highlights the vaccine's preclinical efficacy and thermostability.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 12:31 pm

TSVT

JW Therapeutics has entered into an exclusive collaboration with 2seventy bio for the co-development and commercialization of a CAR-T therapy product for autoimmune diseases in Greater China. JW Therapeutics will handle process development and First-in-Human clinical trials in China, with costs shared by both parties. JW Therapeutics may also negotiate an exclusive license for the product in Greater China and is eligible to receive milestone payments and royalties from 2seventy bio.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 12:29 pm

NVS

VYGR

Voyager Therapeutics, Inc. (VYGR) has entered into a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NVS), to develop gene therapies for Huntington’s disease and spinal muscular atrophy. Voyager will grant Novartis access to its TRACER™ capsids and intellectual property for these diseases, and the two companies will work together on a preclinical gene therapy candidate for Huntington’s disease.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 12:02 pm